The clinical challenge
Similar presentation makes mesothelioma hard to identify1-3
Mesothelioma can be difficult to distinguish from other cancers, particularly in the absence of a single specific and reliable marker
2.
- Lung cancers can vary substantially in appearance and differentiation from microscopic field to field3.
- The diagnostic value of antibodies and immunohistochemical panels is still under debate2.
- Pathological diagnosis often suffers from significant interobserver variability3.
A better diagnostic method is needed
Significant shortcomings are associated with the methods currently used to diagnose mesothelioma
2,3. Pathologists and physicians need a better way to diagnose patients and develop treatment plans in a timely fashion.
Introducing a sensitive and accurate diagnostic test—miRview™ meso
miRview™ meso is a cutting-edge, microRNA-based molecular diagnostic tool that provides physicians and pathologists with a clear, distinct diagnosis in patients with mesothelioma. It differentiates mesothelioma from other cancers of the lung and pleura with:
- Accuracy
- Speed
- Simple interpretation
- Quantitative analysis
- Objective results
- Cutting-edge molecular biology
- Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008;21(9):1084-1094.
- Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132(3):397-401.
- Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.